DRG Epidemiology's coverage of idiopathic pulmonary fibrosis comprises epidemiological estimates of key patient populations globally, including the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom and Japan). We report the prevalence of idiopathic pulmonary fibrosis for each country, as well as annualized case counts projected to the national population.

DRG Epidemiology's idiopathic pulmonary fibrosis forecast will answer the following questions:

  • Of all people with idiopathic pulmonary fibrosis, how many in each country have been formally diagnosed?
  • How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of idiopathic pulmonary fibrosis over the forecast period?
  • How many people with diagnosed idiopathic pulmonary fibrosis also have gastroesophageal reflux disease, pulmonary hypertension, emphysema and obstructive sleep apnea?

All forecast data are available on the DRG Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.

DRG Epidemiology provides at least ten years of forecast data for the following idiopathic pulmonary fibrosis patient populations:

  • Diagnosed prevalent cases
  • Diagnosed prevalent cases with comorbid gastroesophageal reflux disease
  • Diagnosed prevalent cases with comorbid emphysema
  • Diagnosed prevalent cases with comorbid obstructive sleep apnea

Table of contents

  • Idiopathic Pulmonary Fibrosis - Epidemiology - Emerging Markets
    • Introduction
      • Key Findings
        • Overview
          • Prevalence of Idiopathic Pulmonary Fibrosis per 100,000 People Aged 40+ in 2016 and 2027
          • Patient Flow of Idiopathic Pulmonary Fibrosis in the Countries Under Study in 2017
          • Relative Sizes of the Contributing Factors to the Trend in Prevalent Cases of Idiopathic Pulmonary Fibrosis over the Next Ten Years
          • Analysis of the Prevalent Cases of Idiopathic Pulmonary Fibrosis in 2016 by Severity using GAP Stages
          • Number of Additional Prevalent Cases of Idiopathic Pulmonary Fibrosis Incurred Over the Period 2016-2026 Across the Countries Under Study
      • Epidemiology Data
      • Methods
        • Diagnosed Prevalent Cases
        • Diagnosed Incident Cases
        • Severity Stages
        • Diagnosed Prevalent Cases of IPF with Gastroesophageal Reflux Disease
        • Diagnosed Prevalent Cases of IPF with Pulmonary Hypertension
        • Diagnosed Prevalent Cases of IPF with Emphysema
        • Diagnosed Prevalent Cases of IPF with Obstructive Sleep Apnea
      • Reference Materials
        • Literature Review
          • Studies Included in the Analysis of Idiopathic Pulmonary Fibrosis
          • Studies Excluded from the Analysis of Idiopathic Pulmonary Fibrosis
        • Risk/Protective Factors
          • Risk/Protective Factors for Idiopathic Pulmonary Fibrosis
        • Bibliography

    Author(s): Abey John, MPH

    Abey John is a medical graduate with a Master’s in Public Health and has been associated with DRG since September 2015. He works with a global team of epidemiologists in performing systematic reviews of assigned diseases and prepare forecast models for clients. He also is involved in producing analyses for pharmaceutical drug developers on the descriptive epidemiology of major drug indications in mature and developing markets and have an overall experience of three years working in different healthcare sectors across the country.

    Prior to joining DRG, Abey had been working with Jhpiego (an affiliate of Johns Hopkins Medical University) in implementing Family Planning Health Programs in India with collaborating with the Government of India. He also has worked with a grassroots level NGO as a health team manager which worked for the benefit of the rural population living in the foothills of the Himalayas.

    Related Reports

    Idiopathic Pulmonary Fibrosis - Unmet Need - Detailed, Expanded Analysis: (US & EU5)

    Although Ofev and Esbriet are welcome options in the treatment armamentarium for idiopathic pulmonary fibrosis (IPF), therapies that can further d...

    View Details

    Idiopathic Pulmonary Fibrosis - Epidemiology - Extrapolated Worldwide Coverage

    DRG’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key idiopathic pulmonary fib...

    View Details